Adoptive T Regulatory Cell Therapy for Tolerance Induction

Cecilia Cabello-Kindelan, Shane Mackey, Allison L. Bayer

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


There is a clear need to develop strategies to induce tolerance without the need of chronic immunosuppression in transplant recipient and in patients with autoimmunity. Adoptive T regulatory cell (Treg) therapy offers the potential of long-lasting protection. However, based on results of clinical trials so far with ex vivo expanded autologous Tregs in type 1 diabetic (T1D) patients, it seems unlikely that single immunotherapy with Treg infusion without immunomodulation regimens that promote stable donor Treg engraftment and persistence would afford truly significant clinical benefit. Combination therapies could provide improved outcomes with consideration of the fundamental factors required for Treg generation, homeostasis, and function to promote long-term donor Treg persistence to provoke beneficial therapeutic outcomes.

Original languageEnglish (US)
Pages (from-to)191-201
Number of pages11
JournalCurrent Transplantation Reports
Issue number2
StatePublished - Jun 1 2015


  • IL-2
  • T cells
  • T regulatory cells
  • Tolerance
  • Transplantation

ASJC Scopus subject areas

  • Transplantation
  • Surgery
  • Hepatology
  • Nephrology
  • Immunology


Dive into the research topics of 'Adoptive T Regulatory Cell Therapy for Tolerance Induction'. Together they form a unique fingerprint.

Cite this